A
Ashwini Budrukkar
Researcher at Homi Bhabha National Institute
Publications - 168
Citations - 4110
Ashwini Budrukkar is an academic researcher from Homi Bhabha National Institute. The author has contributed to research in topics: Radiation therapy & Breast cancer. The author has an hindex of 30, co-authored 146 publications receiving 3312 citations. Previous affiliations of Ashwini Budrukkar include Tata Memorial Hospital.
Papers
More filters
Journal ArticleDOI
Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.
Rajendra A. Badwe,Rohini Hawaldar,Nita S. Nair,Rucha Vishal Kaushik,Vani Parmar,Shabina Siddique,Ashwini Budrukkar,Indraneel Mittra,Sudeep Gupta +8 more
TL;DR: In this paper, the authors compared the effect of locoregional treatment with no treatment on outcome in women with metastatic breast cancer at initial presentation, and found that there is no evidence to suggest that the treatment of the primary tumor affects overall survival in patients who have responded to front-line chemotherapy.
Journal ArticleDOI
Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis.
Tejpal Gupta,Zubin Master,Sadhana Kannan,Jai Prakash Agarwal,Sarbani Ghsoh-Laskar,Venkatesh Rangarajan,Vedang Murthy,Ashwini Budrukkar +7 more
TL;DR: The overall diagnostic performance of post-treatment FDG PET(CT) for response assessment and surveillance imaging of HNSCC is good, but its PPV is somewhat suboptimal.
Journal ArticleDOI
Volumetric modulated arc radiotherapy for carcinomas of the oro-pharynx, hypo-pharynx and larynx: A treatment planning comparison with fixed field IMRT
Eugenio Vanetti,Alessandro Clivio,Giorgia Nicolini,Antonella Fogliata,Sarbani Ghosh-Laskar,Jai Prakash Agarwal,Ritu Raj Upreti,Ashwini Budrukkar,Vedang Murthy,Deepak D. Deshpande,Shyam Kishore Shrivastava,Ketayun A. Dinshaw,Luca Cozzi +12 more
TL;DR: Target coverage and homogeneity results improved with RA2 plans compared to both RA1 and IMRT, while only RA2 offered improved target coverage with respect to conventional IMRT.
Journal ArticleDOI
Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial.
Tejpal Gupta,Jai Prakash Agarwal,Sandeep Jain,Reena Phurailatpam,Sadhana Kannan,Sarbani Ghosh-Laskar,Vedang Murthy,Ashwini Budrukkar,Ketayun A. Dinshaw,Kumar Prabhash,Pankaj Chaturvedi,Anil K. D'Cruz +11 more
TL;DR: IMRT significantly reduces the incidence and severity of xerostomia compared to 3D-CRT in curative-intent irradiation of head-neck squamous cell carcinoma of HNSCC.
Journal ArticleDOI
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
Vanita Noronha,Amit Joshi,Vijay Patil,Jai Prakash Agarwal,Sarbani Ghosh-Laskar,Ashwini Budrukkar,Vedang Murthy,Tejpal Gupta,Anil K. D'Cruz,Shripad Banavali,Prathamesh S. Pai,Pankaj Chaturvedi,Devendra Chaukar,Nikhil Pande,Arun Chandrasekharan,Vikas Talreja,Dilip Harindran Vallathol,Vijayalakshmi Mathrudev,Aparna Manjrekar,Kamesh Maske,Arati Sanjay Bhelekar,Kavita Nawale,Sadhana Kannan,Vikram Gota,Atanu Bhattacharjee,Shubhada Kane,Shashikant Juvekar,Kumar Prabhash +27 more
TL;DR: Once-every-3-weeks cisplatin at 100 mg/m2 resulted in superior LRC, albeit with more toxicity, than did once-a-week cisplinatin at 30 mg/ m2, and should remain the preferred chemoradiotherapy regimen for LAHNSCC in the adjuvant setting.